Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration

Sy, SK; Sweeney, TD; Ji, CM; Hoch, U; Eldon, MA

Hoch, U (reprint author), Nektar Therapeut, Dept Clin Pharmacol, 455 Miss Bay Blvd South, San Francisco, CA 94158 USA.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017; 79 (1): 57